Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low Dose PTCy/Tacrolimus/Ruxolitinib for GVHD Prophylaxis in MAC Allogeneic PBSCT
NCT07249346Phase 2Recruiting
- Start
- Jan 2026
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ruxolitinib in graft-versus-host disease (GVHD). Started Jan 2026; status: recruiting.
02
Drugs
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT07249346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07249346.